Lesions in the skin and mucosa in a 20-year-old woman with epidermolysis bullosa acquisita (EBA) came back years later, after a COVID-19 vaccination, according to a case report. While rapid development of skin disease after receiving vaccinations had been reported, this is the first case of possible EBA with autoantibodies…
LifeArc and DEBRA Austria have launched a £2.5 million (around $3.3 million) funding call for projects that seek to repurpose therapies for epidermolysis bullosa (EB). Treatment repurposing consists of identifying new therapeutic use for approved medicines. It is an alternative approach to the traditional process of developing…
The U.S. Food and Drug Administration (FDA) has approved a clinical trial in healthy volunteers of ZKN-013, a treatment candidate for recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB). Developed by Eloxx Pharmaceuticals, ZKN-013 is an oral therapy that can overcome nonsense mutations, a…
The 6th annual Plunge for Elodie is set to raise more than $2 million for epidermolysis bullosa (EB) research, EB Research Partnership (EBRP) has announced. The event, taking place from March 25 to April 2, invites supporters to plunge into freezing waters at one of the official…
Get regular updates to your inbox.